vs

Side-by-side financial comparison of CollPlant Biotechnologies Ltd (CLGN) and Valaris Ltd (VAL). Click either name above to swap in a different company.

CollPlant Biotechnologies Ltd is the larger business by last-quarter revenue ($10.2M vs $5.2M, roughly 2.0× Valaris Ltd). Valaris Ltd runs the higher net margin — 13798.1% vs 56.6%, a 13741.5% gap on every dollar of revenue. On growth, CollPlant Biotechnologies Ltd posted the faster year-over-year revenue change (15330.3% vs 405.9%).

CollPlant Biotechnologies Ltd is a regenerative medicine company focused on developing and commercializing advanced products using its proprietary plant-derived human collagen technology. Its core offerings cover wound care, soft tissue repair, and aesthetic medicine solutions, targeting key markets across North America, Europe, and Israel, serving healthcare providers in dermatology, orthopedics and cosmetic care segments.

Valaris Limited is an offshore drilling contractor headquartered in Houston, Texas, and incorporated in Bermuda. It is the largest offshore drilling and well drilling company in the world. As of February 2025, it owned 52 rigs, including 36 offshore jackup rigs, 11 drillships, and 5 semi-submersible platform drilling rigs.

CLGN vs VAL — Head-to-Head

Bigger by revenue
CLGN
CLGN
2.0× larger
CLGN
$10.2M
$5.2M
VAL
Growing faster (revenue YoY)
CLGN
CLGN
+14924.4% gap
CLGN
15330.3%
405.9%
VAL
Higher net margin
VAL
VAL
13741.5% more per $
VAL
13798.1%
56.6%
CLGN

Income Statement — Q2 FY2023 vs Q4 FY2025

Metric
CLGN
CLGN
VAL
VAL
Revenue
$10.2M
$5.2M
Net Profit
$5.8M
$717.5M
Gross Margin
94.0%
-7850.0%
Operating Margin
55.7%
Net Margin
56.6%
13798.1%
Revenue YoY
15330.3%
405.9%
Net Profit YoY
234.5%
436.6%
EPS (diluted)
$0.49
$10.13

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CLGN
CLGN
VAL
VAL
Q4 25
$5.2M
Q3 25
$5.6M
Q2 25
$700.0K
Q4 24
$-1.7M
Q3 24
$3.9M
Q2 24
$4.8M
Q1 24
$2.6M
Q4 23
$3.1M
Net Profit
CLGN
CLGN
VAL
VAL
Q4 25
$717.5M
Q3 25
$188.1M
Q2 25
$115.1M
Q4 24
$133.7M
Q3 24
$64.6M
Q2 24
$149.6M
Q1 24
$25.5M
Q4 23
$828.5M
Gross Margin
CLGN
CLGN
VAL
VAL
Q4 25
-7850.0%
Q3 25
-7142.9%
Q2 25
-56428.6%
Q4 24
24529.4%
Q3 24
-11748.7%
Q2 24
-9039.6%
Q1 24
-17007.7%
Q4 23
-12867.7%
Net Margin
CLGN
CLGN
VAL
VAL
Q4 25
13798.1%
Q3 25
3358.9%
Q2 25
16442.9%
Q4 24
-7864.7%
Q3 24
1656.4%
Q2 24
3116.7%
Q1 24
980.8%
Q4 23
26725.8%
EPS (diluted)
CLGN
CLGN
VAL
VAL
Q4 25
$10.13
Q3 25
$2.65
Q2 25
$1.61
Q4 24
$1.86
Q3 24
$0.88
Q2 24
$2.03
Q1 24
$0.35
Q4 23
$11.12

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CLGN
CLGN
VAL
VAL
Cash + ST InvestmentsLiquidity on hand
$22.3M
$599.4M
Total DebtLower is stronger
Stockholders' EquityBook value
$36.0M
$3.2B
Total Assets
$41.6M
$5.3B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CLGN
CLGN
VAL
VAL
Q4 25
$599.4M
Q3 25
$662.7M
Q2 25
$503.4M
Q4 24
$368.2M
Q3 24
$379.3M
Q2 24
$398.3M
Q1 24
$494.1M
Q4 23
$620.5M
Stockholders' Equity
CLGN
CLGN
VAL
VAL
Q4 25
$3.2B
Q3 25
$2.4B
Q2 25
$2.3B
Q4 24
$2.2B
Q3 24
$2.1B
Q2 24
$2.2B
Q1 24
$2.0B
Q4 23
$2.0B
Total Assets
CLGN
CLGN
VAL
VAL
Q4 25
$5.3B
Q3 25
$4.6B
Q2 25
$4.5B
Q4 24
$4.4B
Q3 24
$4.3B
Q2 24
$4.4B
Q1 24
$4.4B
Q4 23
$4.3B

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CLGN
CLGN
VAL
VAL
Operating Cash FlowLast quarter
$72.2M
Free Cash FlowOCF − Capex
$-34.1M
FCF MarginFCF / Revenue
-655.8%
Capex IntensityCapex / Revenue
2044.2%
Cash ConversionOCF / Net Profit
0.10×
TTM Free Cash FlowTrailing 4 quarters
$159.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CLGN
CLGN
VAL
VAL
Q4 25
$72.2M
Q3 25
$198.1M
Q2 25
$120.0M
Q4 24
$124.6M
Q3 24
$193.0M
Q2 24
$11.5M
Q1 24
$26.3M
Q4 23
$96.7M
Free Cash Flow
CLGN
CLGN
VAL
VAL
Q4 25
$-34.1M
Q3 25
$128.3M
Q2 25
$52.8M
Q4 24
$12.9M
Q3 24
$111.1M
Q2 24
$-98.7M
Q1 24
$-125.0M
Q4 23
$-366.3M
FCF Margin
CLGN
CLGN
VAL
VAL
Q4 25
-655.8%
Q3 25
2291.1%
Q2 25
7542.9%
Q4 24
-758.8%
Q3 24
2848.7%
Q2 24
-2056.3%
Q1 24
-4807.7%
Q4 23
-11816.1%
Capex Intensity
CLGN
CLGN
VAL
VAL
Q4 25
2044.2%
Q3 25
1246.4%
Q2 25
9600.0%
Q4 24
-6570.6%
Q3 24
2100.0%
Q2 24
2295.8%
Q1 24
5819.2%
Q4 23
14935.5%
Cash Conversion
CLGN
CLGN
VAL
VAL
Q4 25
0.10×
Q3 25
1.05×
Q2 25
1.04×
Q4 24
0.93×
Q3 24
2.99×
Q2 24
0.08×
Q1 24
1.03×
Q4 23
0.12×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons